Illumina and D3b partner to analyze 100,000 pediatric genomes, enabling large-scale data sharing, advanced analytics, and faster translation into precision care for rare diseases and childhood cancers.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Illumina and the Center for Data-Driven Discovery in Biomedicine (D3b) announced a data partnership in Q1 2026 to propel pediatric cancer and rare disease research via a unified, cloud-based genomic ecosystem. Global researchers can now analyze pediatric datasets in a single scalable environment, enabling real-time cross-cohort comparisons and faster translation to clinical care.
Building One of the Largest Pediatric Genomic Datasets
D3b will analyze 100,000 whole genomes from pediatric patients using Illumina’s software platforms—one of the largest unified datasets to date. Accessible via the Gabriella Miller Kids First Data Resource Center, this resource empowers researchers and clinicians to probe rare diseases, cancers, and precision medicine applications.
Breaking Data Silos for Better Clinical Insights
Fragmented genomic data across institutions hinders progress against childhood congenital conditions and cancers, top causes of pediatric mortality. This shared ecosystem facilitates case comparisons, diagnosis validation, and treatment guidance from large cohorts, boosting accuracy and decision-making.
Advanced Analytics Fueling Breakthroughs
Genomes from programs like Kids First DRC and Children’s Brain Tumor Network (CBTN) undergo processing with Illumina’s DRAGEN v4.4 and Connected Analytics (ICA). These tools deliver high-speed analysis, correcting sequencing errors and uncovering previously missed structural variants.
Accelerating Data-Driven Pediatric Care
The partnership supports ARPA-H’s Pediatric Care eXpansion (PCX) program under HHS, slashing diagnostic timelines from months to weeks across 200+ U.S. pediatric institutions. Clinicians gain real-world data access for timely, personalized treatments.
Leadership Perspectives
James Han, Illumina’s VP of Bioinformatics, stated: “Large-scale genomic datasets, paired with software and AI advances, drive faster, precise breakthroughs.”
Allison Heath, D3b’s Director of Data Technology and Innovation, added: “Advanced analytics reveal new biological signals, integrating genomics into routine care and redefining pediatric standards.”
Reference
Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease, 14 April Press Release
About the Writer
Chikkula Pavan Kumar, Pharm.D is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.